| Literature DB >> 30408571 |
Xiaojun Feng1, Yi Li1, Yanan Wang1, Lingli Li1, Peter J Little2, Suo-Wen Xu3, Sheng Liu4.
Abstract
Cardiovascular and cerebrovascular diseases are the main cause of mortality worldwide, currently with less than optimum therapeutic options. Danhong injection (DHI) is a medicinal preparation based on two eminent Chinese herbal medicines, Salviae Miltiorrhizae (Dan Shen; family: Lamiaceae) and Flos Carthami (Hong Hua; family: Compositae/Asteraceae). DHI has been mainly used in the clinical therapy of cardiovascular (such as acute coronary syndrome and angina pectoris) and cerebrovascular diseases (such as stroke) in China for many years. The pharmacological properties of DHI include anti-inflammatory, anti-oxidant, anti-coagulatory, hypolipidemic, anti-apoptotic, vasodilatory, and angiogenesis-promoting actions. DHI offers a safe and effective therapeutic agent against cardiovascular and cerebrovascular diseases by modulating multiple disease-relevant signaling pathways and molecular targets. Herein, we provide a comprehensive review of the phytochemistry, therapeutic effects, molecular mechanisms, and adverse reactions of DHI in cardiovascular and cerebrovascular diseases. We also highlight the latest pharmacological advances and therapeutic potential of this promising herb-derived cardiovascular drug preparation.Entities:
Keywords: Atherosclerosis; Cardiac hypertrophy; Cardiovascular diseases; Coronary artery disease; Danhong injection; Danshensu (PubChem CID: 11600642); Ferulic acid (PubChem CID: 445858); Hydroxysafflor yellow A (PubChem CID: 6443665); Protocatechuic aldehyde (PubChem CID: 8768); Rosmarinic acid (PubChem CID: 5281792); Salvianolic acid A (PubChem CID: 5281793); Salvianolic acid B (PubChem CID: 11629084); Salvianolic acid D (PubChem CID: 75412558); Stroke
Mesh：
Substances：
Year: 2018 PMID： 30408571 DOI： 10.1016/j.phrs.2018.11.006
Source DB: PubMed Journal: Pharmacol Res ISSN： 1043-6618 Impact factor: 7.658